The Board of Eliem Therapeutics, Inc. has approved a corporate reorganization plan to conserve financial resources. As part of the reorganization, the Company will reduce its workforce by approximately 55% in the first half of 2023. In connection with this reorganization, Erin Lavelle, chief financial officer will depart the Company following a short transition period.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.46 USD | -5.47% | -16.69% | +213.33% |
Apr. 11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Apr. 11 | Top Midday Gainers | MT |
1st Jan change | Capi. | |
---|---|---|
+213.33% | 237M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Erin Lavelle to Depart as Chief Financial Officer of Eliem Therapeutics, Inc